employee compensation

Arcutis granted 309,000 equity awards to 40 new hires. Company seeks FDA approval to expand ZORYVE cream to treat atopic dermatitis in infants as young as 3 months.

Pacira BioSciences granted inducement equity awards to 10 new employees, including stock options and RSUs valued at approximately $1.5M, under Nasdaq rules.

Absci grants 276,200 non-statutory stock options at $4.92/share to newly hired employee as employment inducement under Nasdaq listing rules.

Zentalis Pharmaceuticals granted 26,000 stock options to new employee at $4.09 exercise price under inducement plan provisions.

NewAmsterdam Pharma approved inducement grants totaling 50,400 options and 15,400 RSUs to five new non-executive employees under Nasdaq compliance rules.

Xilio Therapeutics granted stock options for 3,257 shares to two new employees at $8.48 exercise price, reflecting typical equity compensation practices for biotech hiring.

IN8bio issued 11,800 stock options to two new employees on April 1, 2026, as hiring incentives under Nasdaq listing regulations.

Taysha Gene Therapies grants 300,000 RSUs and options to purchase 92,400 shares to four new employees under its 2023 Inducement Plan.

NewAmsterdam Pharma grants 15,000 options and 3,200 RSUs to two new executives, complying with Nasdaq listing regulations.

Vor Bio awarded stock options and RSUs to nine newly hired employees as employment inducements, with options exercisable at $17.39 per share over a 10-year term.

Zentalis Pharmaceuticals granted 36,000 stock options at $2.57/share to two new hires under Nasdaq inducement rules, vesting over four years.

Quantum BioPharma grants 35,000 stock options to employees at CA$6.50 strike, vesting immediately with five-year exercise window.

Syensqo launches week-long buyback program to repurchase 260,000 shares for employee incentive plan obligations through multiple trading venues.

Cytokinetics granted inducement stock options and RSUs to five new employees hired in early 2026, using Nasdaq listing rule 5635(c)(4) to compensate talent.

Pacira BioSciences awarded stock options and RSUs to three new employees totaling 7,900 shares at $22.10 exercise price under its inducement plan.

BioCryst awards 65,850 RSUs to six new employees under Nasdaq inducement rule, vesting over four years starting March 2027.

Iovance granted 3,600 stock options to two new employees at $2.85/share under NASDAQ inducement plan rules, with three-year vesting.

TELA Bio granted 8,550 restricted stock units to three new hires, vesting over four years. The equity compensation aims to attract talent and promote retention.

CAMP4 Therapeutics granted 8,000 stock options to a new employee at $3.85/share exercise price, using standard four-year vesting under Nasdaq rules for talent attraction.

Elicio Therapeutics granted 30,300 stock options at $8.59 per share to a new employee on February 17, 2026, vesting over four years.